| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.38B | $9.62B | $7.32B | $3.33B | $3.13B | $3.59B | $3.37B | $3.07B |
| Cost of Revenue | $5.29B | $8.42B | $4.24B | $2.32B | $2.13B | $2.33B | $2.16B | $1.96B |
| Gross Profit | $84.24M | $1.20B | $3.08B | $1.01B | $996.85M | $1.26B | $1.22B | $1.11B |
| Gross Margin | 1.57% | 12.45% | 42.05% | 30.30% | 31.86% | 35.06% | 36.07% | 36.13% |
| Operating Expenses | $1.86B | $945.03M | $607.73M | $210.04M | $491.04M | $592.36M | $305.72M | $538.32M |
| Operating Income | $-1.78B | $251.88M | $2.47B | $798.43M | $505.81M | $666.12M | $911.54M | $571.66M |
| Operating Margin | -33.04% | 2.62% | 33.74% | 23.99% | 16.17% | 18.56% | 27.01% | 18.61% |
| Net Income | $-1.18B | $1.57B | $2.69B | $123.67M | $375.76M | $533.23M | $693.56M | $54.85M |
| Net Margin | -21.93% | 16.36% | 36.75% | 3.72% | 12.01% | 14.86% | 20.55% | 1.79% |
| EPS (Basic) | $-11.20 | $13.41 | $22.97 | $1.07 | $3.53 | $5.03 | $6.40 | $0.49 |
| EBITDA | $-9.11M | $897.06M | $2.87B | $875.13M | $742.46M | $943.25M | $1.05B | $759.08M |
| Stock Option Compensation Expense | $32.14M | $36.55M | $30.47M | $20.12M | $22.84M | $19.68M | $15.23M | $19.40M |
| Price To Earnings Ratio | -8.58 | 10.77 | 9.44 | 218.97 | 41.77 | 14.51 | 12.05 | 258.61 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $10.12B | $16.95B | $25.40B | $27.08B | $15.70B | $7.74B | $8.36B | $14.18B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $16.61B | $18.27B | $15.46B | $10.97B | $10.45B | $9.86B | $7.58B | $7.75B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.41B | $8.61B | $7.27B | $5.17B | $5.98B | $5.77B | $3.82B | $3.93B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $9.96B | $9.41B | $7.98B | $5.63B | $4.27B | $3.93B | $3.59B | $3.67B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.96B | $9.41B | $7.98B | $5.63B | $4.27B | $3.93B | $3.59B | $3.67B |
| Total Liabilities & Stockholders Equity | $16.61B | $18.27B | $15.46B | $10.97B | $10.45B | $9.86B | $7.58B | $7.75B |
| Book Value Per Share | $86.79 | $82.38 | $69.94 | $50.12 | $42.00 | $38.64 | $34.67 | $34.42 |
| Tangible Book Value Per Share | $71.36 | $66.26 | $53.67 | $33.66 | $23.06 | $20.39 | $16.65 | $16.10 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -7.10% | 8.61% | 17.40% | 1.13% | 3.60% | 5.41% | 9.15% | 0.71% |
| Return on Equity | -11.84% | 16.72% | 33.70% | 2.20% | 8.80% | 13.56% | 19.34% | 1.49% |
| Return on Invested Capital | -11.81% | 1.31% | 17.06% | 7.33% | 4.77% | 6.71% | 11.12% | 0.27% |
| Quick Ratio | 1.19 | 0.86 | 1.13 | 0.64 | 0.81 | 1.03 | 1.10 | 1.57 |
| Current Ratio | 1.95 | 1.47 | 1.89 | 1.06 | 1.22 | 1.58 | 1.69 | 2.06 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.18B | $1.57B | $2.69B | $123.67M | $375.76M | $533.23M | $693.56M | $54.85M |
| Depreciation | $588.64M | $429.94M | $300.84M | $254.00M | $231.98M | $213.48M | $200.70M | $196.93M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $702.07M | $1.33B | $1.91B | $344.26M | $798.91M | $719.37M | $546.16M | $303.98M |
| Capital Expenditures | $1.69B | $2.15B | $1.26B | $953.67M | $850.48M | $851.80M | $699.99M | $317.70M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $311.28M | $187.19M | $184.43M | $177.85M | $161.82M | $152.20M | $144.60M | $140.56M |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $500.00M | $250.00M |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $-983.72M | $-823.96M | $646.20M | $-609.41M | $-51.56M | $-132.42M | $-153.83M | $-13.72M |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts. The Lithium division supplies a variety of lithium compounds, including lithium carbonate, hydroxide, and chloride, alongside critical reagents like butyllithium. These materials are vital for manufacturing lithium-ion batteries found in electric vehicles and consumer electronics, as well as for high-performance greases, thermoplastic elastomers used in tires and plastics, and as catalysts for chemical reactions, organic synthesis in areas like steroid chemistry, vitamins, and the pharmaceutical industry. This segment also delivers cesium products for chemical and pharmaceutical applications, zirconium, barium, and titanium for pyrotechnic devices such as airbag initiators, offers expert technical services for the safe handling of reactive lithium products, and provides recycling solutions for lithium-containing by-products. The Bromine segment focuses on bromine and bromine-based fire safety compounds. It produces an array of specialty chemicals, including elemental bromine, various bromides, and brominated powdered activated carbon, which are utilized in chemical synthesis, fluids for oil and gas drilling, mercury emission control, water purification, and food processing. Additionally, it provides tertiary amines, which serve as key ingredients in surfactants, biocides, and sanitizers. Finally, the Catalysts segment offers a range of catalytic agents, including those for hydroprocessing, isomerization, and alkylation, alongside fluidized catalytic cracking (FCC) catalysts and additives, as well as organometallics and curatives. Albemarle's products are integral to numerous industries, including energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection. Established in 1887, the company's headquarters are located in Charlotte, North Carolina.
Why it moved over time
Albemarle Corporation (ALB) beat Q2 2026 earnings on stronger lithium pricing and Specialties growth, lifting EBITDA, cash flow and guidance—improving the company's near-term profit outlook and balance-sheet metrics.
Key fact: Beat Q2 2026 earnings estimates driven by stronger lithium pricing and Specialties growth
zacks.com: ALB Q2 Earnings Beat Estimates on Lithium Pricing StrengthAlbemarle reported Q2 EPS of $3.75 versus a $3.35 consensus, a beat that likely prompted investor reassessment of near-term profitability and the company's outlook.
Key fact: Q2 EPS $3.75 vs. $3.35 consensus estimate.
zacks.com: Albemarle (ALB) Q2 Earnings and Revenues Surpass EstimatesInvestors are positioning ahead of Albemarle's Q2 (June) earnings, with Wall Street previews and unusual options activity signaling heightened focus on results and guidance that could alter lithium demand outlook.
Key fact: Wall Street previews (Aug 3) and an options-activity report (Jul 31) highlight market focus on ALB's upcoming June-quarter earnings.
zacks.com: Gear Up for Albemarle (ALB) Q2 Earnings: Wall Street Estimates for Key MetricsOptions activity and analyst previews indicate investors are positioning ahead of Albemarle's Q2 (June) earnings, signaling expectations and potential stock volatility when the company reports.
Key fact: Recent Zacks articles this week preview Wall Street Q2 estimates and note elevated options-market interest in ALB.
zacks.com: Gear Up for Albemarle (ALB) Q2 Earnings: Wall Street Estimates for Key Metrics